EnWave Corporation

Good morning. Welcome to NWAVE Corporation's Q2 2024 earnings conference call. My name is Daryl, and I will be your operator for today's call. Joining us for today's presentation are company's president and CEO, Brett Charlton, and Dylan Murray, NWAVE's CFO. As a reminder, all participants are in a listen-only mode, and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Finally, I would like to remind everyone that this call will be made available for replay via a link in the investor relations section of the company's website at www.nwave.net. Now, I would like to turn the call over to NWAVE CEO, Mr. Brent Charlton. Sir, please proceed.

Thank you, and thanks to all of you who have joined us today to discuss NWAVE Corporation's Q2 performance and our outlook for the rest of fiscal 2024. Now, consistent with past quarterly earnings calls, the information we will present today contains forward-looking information that is based on our management's expectations, estimates, and projections. Our statements are not a guarantee of future performance and involve a number of risks, uncertainties, and assumptions. Please consider the risk factors in the filings made by NWAVE on CDAR when reviewing this information. Also, all amounts discussed will be in Canadian dollars unless otherwise noted. NWAVE's second fiscal quarter of 2024 has effectively set the stage for stronger performance throughout the remainder of 2024 and beyond. We continue to achieve positive momentum in our royalty growth, but we were unable to complete new purchase orders for radiant energy vacuum machinery from new or existing royalty partners prior to the completion of the quarter. However, Earlier this week, we confirmed a new 120 kilowatt purchase order from an existing royalty partner to support their need for increased manufacturing capacity tied to opportunities with several major consumer packaged goods brands. And then, this morning, we announced a second large-scale rev machine sale, the second in one week. The deal announced this morning is the sale of the 100 kilowatt machine that was previously being used by Nutri-Dried and was not included in the asset sale of the Moochies brand and certain other machinery to Creations Foods earlier this year. This 100 kilowatt sale to BranchOut Foods will yield a very healthy margin profit to EnWave and allow BranchOut to ramp up production capacity for their line of snack products very quickly. BranchOut has enjoyed tremendous sales success in recent months. Further to these two deals, we are well advanced on a number of similar opportunities that could be confirmed this fiscal year. If these opportunities come to fruition, we expect to deliver an exceptionally better second half of the fiscal year. Royalty growth continues to be a strong quarter over quarter, and this is the key metric that investors should continue to focus on. As we continue to grow our diversified portfolio of royalty streams, we will get closer to covering our baseline expenses, and we will become less susceptible to machine sales and their impacts on revenue margins and EBITDA quarter to quarter. In regards to expense control, we've been diligent in maintaining a reasonable structure and have been extremely critical regarding discretionary spending. In Q2 and to the date of this call, we did close two new technology evaluation agreements, one with a U.S.-based cannabis company and one with a company led by a Michelin star chef. The cannabis agreement is expected to conclude in June when the evaluating company will decide to move forward with rev machinery acquisition or not. The evaluation associated with the Michelin star chef is expected to continue through Q4 as they have a more robust new product development plan. We also signed a new commercial licensing Q2 with an established South American food company. They agreed to lease two 10-kilowatt machines for initial product development and commercial sales. Unfortunately, it took this company until May to coordinate the receipt of these machines due to unforeseen tax issues. We expect this project to intensify in the coming months and a decision from this licensed royalty partner regarding large-scale machinery in calendar 2024. One additional bright spot in Q2 was the confirmation of a material toll manufacturing contract with BranchOut Food, a current royalty partner who is growing its business significantly, to use our RevWorks facility to produce Brussels sprouts for their snack portfolio. We have been producing products for BranchOut since March and expect to continue production until August, if not longer. There is a high likelihood that additional orders will be confirmed due to large repeat orders from BranchOut's customers, extending the engagement at RevWorks longer term. We have other companies scheduled for line trials this summer, and we are optimistic regarding additional utilization of RevWorks beyond this large current contract. Looking forward now to the rest of Q3 and Q4, the efforts of our team throughout Q2 has laid the groundwork for multiple 10-kilowatt and large-scale machine sale opportunities. Repeat orders from existing royalty partners, new licensees, and research and development organizations are all possible. Some of these projects are focused on new commercial product areas, including pet treats, seafood products, and cosmetic applications. And as indicated by our royalty growth, several of our key royalty partners are enjoying increased success in market, and we believe this should continue. The aforementioned recently announced 120 kilowatt machine sale to an existing royalty partner, and then 100 kilowatt machine sale to Branch Out Foods, clearly welcomed Q3 steps forward in the right direction. Our expectations, is that the machine should reach full capacity utilization in 2025 as the purchaser has many high volume co-manufacturing projects lined up. This is the 120 kilowatt machine. And it's possible that we could see another large scale order from that same partner within the next 12 months based on their current pipeline. Now over the past three years, EnWave has sold between four and six large scale rev machines per year. With the opportunities identified and sales efforts invested year-to-date, we believe we are well-positioned to yield similar performance in fiscal year 2024. Events of fiscal Q2 have confirmed for us that the market interest for REV technology is strong and that sales opportunities are therefore robust. It also suggests to me that there may be an opportunity to invest in and potentially expand our internal sales structure to tighten sales cycles and potentially increase NWA's annual large machine sales cadence from four to six as it has been historically to eight to 10 machines. While more assessment work is required, we've identified certain international markets where we may be able to expedite sales opportunities with strategic in-market hires. I'll share more details on the results of our assessment and our growth plans in the coming months. However, there's no question that now is the time to drive growth and having a more robust sales structure in place should help improve NLA's future performance. Our technology is advanced The commercial success of many of our royalty partners is evident, and our pipeline of blue-chip prospects is growing. I'll now ask Dylan to summarize Enway's detailed quarterly financial performance.

Thanks, Brent. Good morning, everyone, and thank you for joining us today. Please note that the figures I'll be going over today can be found in our press release from yesterday and in the financial statements an MD&A filed on CDAR, and all amounts are in Canadian dollars unless otherwise noted. I will make reference to adjusted EBITDA, which is a non-IFRS financial measure. So please refer to the non-IFRS financial measure disclosures and reconciliation to gap net income, both in the press release and RMDNA. Also, please note that the comparative period I'll refer to throughout this presentation is the prior year Q2 ended March 31st, 2023. Revenues for Q2 were $663K compared to $4.64 million in Q2 2023, a decrease of $3.97 million or 86%. The decrease was primarily related to fewer machine sales and machines and fabrication during the period and two machine flips in the comparative period. The decrease in revenue was partially offset by third-party royalty revenue, which was $414K in Q2 2024 compared to $277K in Q2 2023, an increase of $137K or 49%. Royalties grew due to increased partner product sales and production. And as our royalty partners grow their businesses and increase capacity utilization on REV equipment alongside new REV installations arising from new sales, we hope to see material royalty growth over the coming quarters. Gross margin for the company in Q2 2024 was negative 25% compared to 49% in Q2 2023. The decrease in margin was a result of no new machine sales and fewer machines in fabrication to absorb fixed overhead costs and two strategic machine redeployments in the comparative period. SG&A expenses, including R&D, were $1.39 million for Q2 2024, which was consistent with a comparable period in the prior year. As Brent mentions, the company continues to make concerted efforts to manage its discretionary spending. Adjusted EBITDA is a non-IFRS financial measure, so please refer to our MD&A for the reconciliation from gap net income to adjusted EBITDA. The company reported an adjusted EBITDA loss of $1.27 million for Q2 2024 compared to an adjusted EBITDA profit of $1.15 million for Q2 2023, a decrease of $2.42 million. The decrease in adjusted EBITDA was primarily related to no new machine sales and fewer machines in fabrication during the period and the two strategic redeployments of the comparative period. We finished the quarter with cash and cash equivalents of $3.16 million and a networking capital surplus of $6.31 million as of March 31st. our balance sheet remains debt-free.